Targeted protein degradation refers to the use of small molecules to induce the selective
degradation of proteins. In its most common form, this degradation is achieved through …

Covalent inhibitors and other types of covalent modalities have seen a revival in the past two
decades, with a variety of new targeted covalent drugs having been approved in recent …

BRD9 is a pivotal epigenetic factor involved in cancers and inflammatory diseases. Still, the
limited selectivity and poor phenotypic activity of targeted agents make it an atypically …

Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that have
emerged as a therapeutic modality to induce targeted protein degradation (TPD) by …

Proteolysis-targeting chimeras (PROTACs) describe compounds that bind to and induce
degradation of a target by simultaneously binding to a ubiquitin ligase. More generally …

Molecular glues and bifunctional small molecules, such as targeted protein degraders,
induce protein proximity to mediate gain-of-function pharmacology. Emerging technologies …

Sulfonyl fluoride EM12-SF was developed previously to covalently engage a histidine
residue in the sensor loop of cereblon (CRBN) in the E3 ubiquitin ligase complex …

Abstract Proteolysis Targeting Chimeras (PROTACs), a groundbreaking technology that has
revolutionized the landscape of targeted protein degradation and therapeutics, is a clinically …

Proteolysis-targeting chimeras (PROTACs) are emerging new therapeutic modalities that
facilitate the targeted degradation of disease-relevant proteins via an event-driven mode of …

Signal transducer and activator of transcription 3 (STAT3) has been widely considered as a
therapeutic target for various diseases, especially tumors. Thus far, several STAT3 inhibitors …